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Abstract
Introduction: The aim of this study was to evaluate the influence of body mass changes on plasma concentrations of proinflammatory 
cytokines in obese women after the initially obtained weight reduction in a five-year follow-up period. 
Material and methods: Thirty out of 42 women with simple obesity (age 41.8 ± 11.9 years; BMI 36.5 ± 4.6 kg/m2) who achieved a greater 
than 5% weight loss at the end of a three-month weight loss programme were re-examined after five years. In addition to anthropometric 
and body composition measurements, plasma concentrations of TNF-alpha, sTNFRs and IL-6 were determined. 
Results: The mean weight loss after the three-month weight loss programme was 7.9 ± 4.4 kg. After five years, body mass was still lower 
than initially in 14 women, while in 16 it was higher (the so-called ‘yo-yo effect’). A significant decrease of plasma TNF-a and IL-6 and 
increase of sTNFR1 and sTNFR2 levels obtained after weight loss therapy were maintained after five years, including in the subgroup 
with the yo-yo effect. During the follow-up period, the increase of body fat mass was similar in the subgroup that maintained reduced 
weight (+4.4 ± 10.7 kg) and in the subgroup with the yo-yo effect (+4.1 ± 7.1 kg), while a significant difference was found in changes of 
body free fat mass (–7.1 ± 7.1 v. –0.7 ± 4.5 kg, respectively).
Conclusions: The yo-yo effect has a modest influence on systemic microinflammation and seems not to abolish the benefit achieved via 
a weight loss programme. This may suggest that the persistence of changes in lifestyle implemented during the programme such as 
regular physical activity and diet composition may have a significant impact on the level of systemic microinflammation in the obese. 
(Endokrynol Pol 2012; 63 (6): 432–438)
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Streszczenie
Wstęp: Celem pracy była ocean wpływu zmian masy ciał w pięcioletniej obserwacji na stężenie w osoczu cytokin prozapalnych u otyłych 
kobiet po wcześniejszej redukcji masy ciała.
Materiał i metody: Trzydzieści z 42 kobiet z otyłością prostą bez chorób towarzyszących (wiek 41,8 ± 11,9 lat; BMI 36,5 ± 4,6 kg/m2), które 
w czasie trzymiesięcznego programu uzyskały co najmniej 5% redukcję masy ciała, zostało zbadanych ponownie po 5 latach. Wykonano 
pomiary antropometryczne i składu ciała oraz oznaczono stężenie w osoczu TNF-alfa, sTNFRs i IL-6.
Wyniki: Średnia redukcja masy ciała w czasie 3 miesięcznego programu wynosiła 7,9 ± 4,4 kg. Po 5 latach u 14 kobiet masa ciała była nadal 
niższa niż początkowa, podczas gdy u 16 była wyższa (efekt jo-jo). Istotne obniżenie stężeń w osoczu TNF-a i IL-6 oraz wzrost stężeń 
sTNFR1 i sTNFR2, które zaobserwowano po redukcji masy ciała, utrzymały się po okresie 5 lat również w podgrupie, w której wystąpił 
efekt jo-jo. W czasie obserwacji przyrost masy tłuszczu był porównywalny w podgrupie, która utrzymała zredukowaną masę ciała (+ 4,4 ± 
± 10,7 kg) i w podgrupie, w której wystąpił efekt jo-jo (+ 4,1 ± 7,1 kg). Podczas gdy w zmianach masy beztłuszczowej zaobserwowano 
istotne różnice (odpowiednio –7,1 ± 7,1 v. –0,7 ± 4,5 kg). 
Wnioski: Efekt jo-jo wywiera niewielki wpływ na nasilenie układowej reakcji zapalnej i wydaje się nie powodować utraty korzyści 
osiągniętych w czasie programu redukcji masy ciała. Może to sugerować, że kontynuowanie zmian stylu życia realizowanych w czasie 
programu, takich jak regularna aktywność fizyczna i skład diety wywierają istotny wpływ na nasilenie układowej reakcji zapalnej u 
otyłych.  (Endokrynol Pol 2012; 63 (6): 432–438)
Słowa kluczowe: czynnik martwicy nowotworów, interleukina-6, zmiany masy ciała 
The study was supported from the Medical University of Silesia grant.
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Introduction
There is no doubt that obesity, namely an excessive 
accumulation of visceral adipose tissue, is a cause of 
systemic microinflammation. Numerous studies have 
revealed elevated circulating TNF-a and IL-6 levels 
in obese subjects [1–7]. Increasing adipocytes volume 
during weight gain is followed by infiltration of adi-
pose tissue with macrophages that become a source 
of cytokines and stimulator of their synthesis by adi-
pocytes [8–13]. Increased release of proinflammatory 
cytokines in adipose tissue is followed by changes of 
adipokine synthesis, impaired lipids accumulation in 
adipocytes, and insulin resistance development [14, 
15]. These disturbances are the reason for ectopic lipids 
accumulating in myocytes and hepatocytes, with the 
subsequent development of insulin resistance within 
these tissues [16–18]. Moreover, changes of adipokines 
release, especially elevated TNF-a and IL-6 as well as 
low adiponectin level, are factors inducing peripheral 
insulin resistance [19,20]. Systemic microinflammation 
associated with obesity is also a cause of atherosclero-
sis [21], hypertension [22] and nonalcoholic fatty liver 
disease [23, 24] development.
It has been shown that as little as a 5–10% weight loss 
results in significant improvements of insulin sensitivity, 
lipid profile and blood pressure [25–28]. Our previously 
published studies revealed that an approximately 10% 
weight loss is associated with significant decreases of 
circulating TNF-a and IL-6 levels [29, 30]. However, 
we observed no correlation between reduced levels of 
these proinflammatory cytokines and insulin sensitiv-
ity improvement [30, 31]. Diminished systemic micro-
inflammation after weight loss has also been revealed 
by several other studies [32–35]. The results of our 
recently published study are particularly interesting in 
this regard, as they revealed that plasma TNF-a level 
is an early event in abdominal fat accumulation and 
that further fat mass gain does not enhance circulating 
TNF-a levels [36]. However, there is no data showing 
how the yo-yo effect affects the concentration of TNF-a, 
sTNFRs and IL-6. Therefore, the aim of this study was 
to evaluate the impact of body mass changes on plasma 
concentrations of proinflammatory cytokines after 
a five-year follow-up in obese women who had achieved 
an initial weight reduction. 
Material and methods 
Forty-two obese women without any concomitant 
diseases who had participated in a three-month group 
weight loss programme in 2000 and 2001 and obtained 
significant weight loss (i.e. 5% or more) were invited 
for re-examination after five years. The characteristics 
of the initial study groups and programme recommen-
dations have been published previously [29]. A total of 
30 women accepted the invitation for a check-up (per-
formed in 2005 and 2006). Only the re-examined subjects 
were included in the statistical analysis. The study was 
approved by the Institutional Bioethical Committee and 
informed consent was obtained from each participant.
All study subjects included in the study were dia-
gnosed as having simple obesity without concomitant 
diseases. The exclusion criteria included: evidence of 
present or recent (in the last three months) infectious 
disease, cigarette smoking and any medication. Medical 
history, physical examination, anthropometric measure-
ments (body mass, height and waist circumference), 
body composition assessment by bioimpedance method 
using the Bodystat 1500 analyser (United Kingdom) 
were performed during the initial and follow-up check-
up. The characteristics of the analysed group are set 
out in Table I.
To analyse the impact of the yo-yo effect (defined as 
weight regain to the baseline or higher) on changes of 
TNF-a, sTNFRs and IL-6 levels, the study women were 
divided into subgroups with and without the effect that 
occurred during the five-year period (Table II). 
Plasma concentrations of TNF-a, sTNFRs as well 
as IL-6 were measured using a commercially available 
Table I. The anthropomettric parameters, the effect of weight reduction treatment and changes during 5-year period (n=30)
Tabela I. Parametry antropometryczne, ich zmiany po kuracji odchudzającej i w 5-letnim okresie obserwacji
Baseline After weight loss D 5-year follow-up D
Body mass [kg] 95.3 ± 16.0 87.4 ± 13.6*** –7.9 ± 4.4 95.0 ± 18.0††† 7.6 ± 6.6
BMI [kg/m2] 36.7 ± 4.8 33.8 ± 4.4 *** –2.9 ± 1.7 36.6 ± 5.7 ††† 2.8 ± 2.4
Body fat [kg] 43.2 ± 12.9 36.9 ± 9.1*** –6.3 ± 7.3 46.6 ± 14.5 ††† 9.7 ± 10.5
Body fat (%) 44.6 ± 9.5 41.3 ± 7.0 * –3.3 ± 6.9 48.2 ± 7.1 ††† 6.9 ± 7.9
Fat-free mass [kg] 52.1 ± 7.2 50.5 ± 6.5 –1.6 ± 6.2 48.4 ± 6.6 † –2.2 ± 4.4
Fat-free mass (%) 55.4 ± 9.4 58.7 ± 6.7 * 3.3 ± 6.7 51.8 ± 7.1 ††† –6.9 ± 5.3 
Waist circumference [cm] 107.2 ± 11.5 99.0 ± 10.4 *** –8.2 ± 4.1 108.4 ± 13.4 ††† 9.4 ± 7.1
*p < 0.05; ***p < 0.001 v. baseline; † p < 0.05; ††† p < 0.001 v. after weight loss
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highly sensitive enzyme-linked immunosorbent assay 
(ELISA) kit (R&D Systems, Minnesota, MN, USA). The 
sensitivity of the TNF-a and IL-6 assays are typically 
less than 0.18 pg/mL. Mean intra-assay coefficient of 
variance was < 14.4% and 10.0% respectively and 
mean interassay coefficient of variance was < 18.7% 
and 10.0% respectively. The sensitivity of the sTNFR1 
and sTNFR2 assays is typically less than 0.77 pg/mL and 
0.6 pg/mL, respectively. Mean intra-assay coefficients 
of variances were < 3.6% and 2.6% respectively and 
mean interassay coefficients of variances were < 3.7% 
and 3.5% respectively. The kits for the TNF system at 
the baseline and follow-up were produced by R&D. 
The assessments were performed at the same analyser. 
The plasma specimens were stored at –80°C for up to 
six months. 
Statistical analysis
All statistical analyses were performed using Statistica 
8.0 software. Results are presented as means ± SD. 
The results were tested with the use of ANOVA with 
Newman-Keuls correction. Wilcoxon rank-sum tests 
(for continuous and ordered variables) and Fisher ’s 
exact tests (for discrete variables) were used to compare 
baseline and post-treatment and post-follow-up clinical/ 
/Laboratory characteristics inside the study subgroups. 
The Mann-Whitney U test was used for subgroup com-
parisons. The Spearman rank-order test was used to 
calculate the univariate correlation coefficients between 
changes of body mass, body composition and waist 
circumference and changes of plasma TNF-a, sTNFR1, 
sTNFR2 levels and IL-6. Multivariate stepwise analysis 
was performed for changes of plasma TNF-a, sTNFR1, 
sTNFR2 and IL-6 levels as the dependent variables, and 
we used age, changes of body fat and waist circumfer-
ence as the independent variables.
The results were considered as statistically signifi-
cant with a p value of less than 0.05.
Results 
Three-month weight loss therapy resulted in mean 7.9 ± 
± 4.4 kg weight loss in all study subjects. It was followed 
by a decrease of BMI from 36.7 ± 4.8 to 33.7 ± 4.4 kg/m2 
and some significant changes in body composition. The 
amount of body fat decreased much more than did fat 
free mass, by 6.3 ± 7.3 and 1.6 ± 6.2 kg respectively. 
During the re-examination carried out five years 
later, a mean weight gain of 7.6 ± 6.6 kg from the values 
at the end of the three-month weight reduction therapy 
was found. The changes of body mass and body com-
position in the study group are presented in Table I.
During the five-year follow-up, 14 study subjects 
maintained lower body mass than initially, while the Ta
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yo-yo effect occurred in 16 women (Table II). The weight 
loss and waist circumference decrease were similar in 
both subgroups after the three-month weight loss ther-
apy. However, the changes of body composition during 
therapy differed significantly. In the subgroup without 
a later yo-yo effect, weight reduction was mainly due 
to the loss of free fat mass, while in the subgroup with 
later yo-yo effect it was mainly due to the loss of fat 
mass (Table II and Fig. 1). During the five-year follow-up 
period, weight regain was observed in both subgroups. 
As predefined, in the subgroup without the yo-yo effect 
body mass, BMI and subsequently waist circumference 
were lower, while in the subgroup with the yo-yo effect 
they were higher than initially. Regardless of weight 
changes, the increase of body fat mass was similar. 
The free fat mass decreased significantly only in the 
subgroup without the yo-yo effect (Table II and Fig. 1).
Markers of systemic microinflammation
Serum concentrations of TNF-a and IL-6 decreased 
significantly after weight loss therapy (Table III). How-
ever, we did not observe changes of these parameters 
after weight regain during re-examination after the 
five-year follow-up period, while serum concentrations 
of sTNFR1 and sTNFR2 increased significantly after 
weight loss, and remained significantly increased after 
the five-year follow-up period (Table III). 
In the subgroup analysis, a greater and significant 
decrease of serum TNF-a level after weight loss therapy 
was observed in the subgroup with the yo-yo effect, 
while the changes of sTNFRs and IL-6 concentrations 
were not significant in either subgroup (Table IV). In 
the five-year re-examination, concentrations of TNF-a, 
sTNFR2 and IL-6 levels were not significantly different 
than previously, while sTNFR1 level was increased in 
the subgroup without the yo-yo effect. In the subgroup 
with the yo-yo effect, plasma TNF-a level was signifi-
cantly lower than initially and similar to the after weight 
loss therapy measurements; sTNFR1 concentration 
was significantly higher than at baseline. The levels of 
sTNFR2 and IL-6 did not change significantly (Table IV). 
Correlation between anthropometric  
parameters and study cytokines 
There was no correlation between changes of body 
mass, BMI, body fat and weight circumference and 
changes of serum concentrations of TNF-a and sTNFR2 
after both weight loss and the following weight regain 
in the whole study group. 
After the three-month weight loss therapy, a positive 
correlation between the decrease of body mass, BMI 
or waist circumference and increase in sTNFR1 levels 
(R = 0.48, p < 0.01; R = 0.41, p = 0.02 and R = 0.44, 
p = 0.02, respectively) was found. However, we ob-
served no correlation between changes of these pa-
rameters after the five-year follow-up period. There 
was a negative correlation between changes of IL-6 in 
the five-year re-examination (from baseline) and cor-
responding changes of weight, body fat mass and waist 
circumference (R = –0.44, p = 0.02; R = –0.41, p = 0.02 
and R = –0.42, p = 0.02, respectively). We found also 
a negative correlation between five-year changes (from 
baseline) of BMI and IL-6 values (R = –0.48, p < 0.01). 
In the subgroup without the yo-yo effect, a strong 
positive correlation between changes of sTNFR1 levels 
induced by the three-month weight loss therapy and 
Table III. Changes of serum concentrations of proinflammatory cytokines in all study subjects (n=30)
Tabela III. Zmiany stężeń w surowicy cytokin prozapalnych w całej grupie badanej (n = 30)
Baseline After weight loss D 5-year follow-up D
TNF-a [pg/mL] 7.1 ± 2.3 5.5 ± 1.7 ** –1.6 ± 1.9 5.7 ± 2.1* 0.2 ± 2.3
sTNFR1 [pg/mL] 1257 ± 234 1425 ± 323** 168 ± 270 2061 ± 508*** 636 ± 600
sTNFR2 [pg/mL] 1729 ± 421 2066 ± 339** 337 ± 397 2120 ± 418*** 54 ± 538
IL-6 [pg/mL] 10.9 ± 4.6 8.8 ± 2.3** –2.1 ± 4.5 7.9 ± 3.5** –0.9 ± 4.1
*p < 0.05; **p<0.01; ***p < 0.001 v. baseline 
Figure 1. Changes of body composition in study subgroups. 
**p < 0.01; ***p < 0.001 v. baseline, ++p < 0.01 v. after weight loss 
Rycina 1. Zmiany składu ciała w badanych podgrupach. 
**p<0,01; ***p<0,001 v. przed kuracją; ++p<0,01 v. po 
redukcji masy ciała
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percentage of free fat mass (R = 0.70, p = 0.01) but nega-
tive with percentage of body fat (R = –0.67, p = 0.02) and 
body fat mass (R = –0.64, p = 0.02) was found. Moreover, 
there was a positive correlation between initial and after 
five-year changes of sTNFR1 and initial and after weight 
loss changes of BMI (R = 0.59, p = 0.03). 
In the subgroup with the yo-yo effect, there was 
a positive correlation between changes of sTNFR1 levels 
induced by the three-month weight loss therapy and 
corresponding changes of body mass, BMI, free fat 
mass as well as waist circumference (R = 0.66, p = 0.01; 
R = 0.52, p = 0.04; R = 0.52, p = 0.04 and R = 0.58, 
p = 0.02, respectively). Moreover, we observed a posi-
tive correlation between changes of IL-6 induced by the 
three-month weight loss therapy and corresponding 
changes of free fat mass (R = 0.52, p = 0.04). Further-
more, there was a positive correlation between induced 
by three-month weight loss therapy changes of free 
fat mass and five-year changes of IL-6 (from baseline) 
(R = 0.57, p = 0.02), but negative between changes of 
BMI, percentage of body fat, body fat mass and waist 
circumference and of those of IL-6 (R = –0.76, p = 0.001; 
R = –0.56, p = 0.03; R = –0.53, p = 0.04 and R = –0,59, 
p = 0.02, respectively). Additionally, a positive correla-
tion between five-year changes of waist circumference 
and corresponding changes of IL-6 (R = 0.51, p = 0.04) 
was shown. 
Multivariate stepwise analysis did not reveal any 
significant data.
Discussion 
The results of our study support previously published 
data showing a significant decrease of circulating 
TNF-a and IL-6 levels, and an increase of sTNFRs, after 
short term weight loss [29, 30, 32–37]. The novelty of 
the presented results is the lack of rebound of TNF-a 
system activity in subjects with the yo-yo effect in the 
five-year follow-up. The explanation of this finding is 
not related to body fat mass, as this increased both in 
obese women who maintained decreased body mass 
and in those with the yo-yo effect. Therefore we should 
assign the changes observed in the five-year follow-up 
to some lifestyle changes such as physical activity and 
diet composition. It has been recently reported that 
regular aerobic exercise training (walking and jogging) 
up to 65% of maximal heart rate, three times a week 
for 24 weeks and omega-3 polyunsaturated fatty acids 
(N-3 PUFAs) supplementation results in significantly 
decreased TNF-a level [38]. Additionally, it has been 
shown that reduced fat intake from 36% to 27% of daily 
energy consumption with high amount of fish-derived 
N-3 PUFAs decreases production of IL-1b and TNF-a 
by peripheral blood mononuclear cells [39]. Moreover, Ta
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some authors have observed that physical activity alone 
may decrease systemic microinflammation [40]. On 
the other hand, another study has revealed that the 
decrease in TNF-a, sTNFRs and IL-6 is only the effect 
of weight loss with significant total and intra-abdominal 
adipose tissue reduction and that exercise did not alter 
the response [41]. 
As described above in both study groups, we ob-
served a significant increase in sTNFRs and decrease 
in IL-6 level. It should be emphasised that only the in-
crease of sTNFR1 was proportional to body mass, BMI or 
waist circumference changes. There was no association 
between changes of anthropometric parameters and 
sTNFR2 as well as IL-6 levels. However, when study 
subjects were divided into subgroups, the numbers 
of study subjects in the analysis declined, and only 
a tendency to increase sTNFRs and decrease IL-6 after 
weight loss therapy persisted. The results of studies 
assessing the effect of weight loss on sTNFRs levels are 
inconsistent. It has been reported that weight loss is 
followed by increased sTNFRs levels [29, 31], decreased 
only sTNFR2 level and not changed sTNFR1 [32], and 
decreased both sTNFR1 and sTNFR2 levels [40]. Simi-
larly conflicting results have been reported from studies 
evaluating the effect of exercise on their concentrations 
[42, 43]. The differences may be due to age and obesity 
grade differences between study subjects. 
It is worth noting that changes of nutritional status 
during the five-year follow-up did not alter the de-
creased TNF-a and IL-6 and increased sTNFRs after 
weight loss. In the subgroup with the yo-yo effect, 
a lower than initially TNF-a level was maintained, while 
plasma sTNFR1 level was significantly higher in both 
study subgroups. This aligns with our recently pub-
lished results which revealed that plasma TNF-a level 
is an early event in abdominal fat accumulation and 
that further fat mass gain does not enhance circulating 
TNF-a levels [36]. 
To the best of our knowledge, this is the first report 
assessing the effect of weight loss and following weight 
changes on plasma TNF-a, sTNFRs and IL-6 levels. 
More detailed explanation of the observed differences is 
difficult and requires further studies involving a larger 
group, homogeneous in terms of age, and controlled 
for physical activity and diet composition. 
Despite the fact that multivariate stepwise analysis 
evaluating the association between changes of study 
cytokines and changes of anthropometric parameters 
did not reveal any significant data, it cannot be excluded 
that the observed differences between study subgroups 
were partially caused by varying profiles of body 
composition after weight loss and subsequent weight 
regain. In this aspect, our study revealed some interest-
ing results. Firstly, regardless of the completion of the 
same educational programme and receiving similar 
recommendations, some of the study women achieved 
weight loss mainly due to loss of fat free mass, while 
in the remainder it was due to body fat reduction. It 
should be emphasised that in both these subgroups the 
waist circumference significantly decreased. Secondly, 
we observed the yo-yo effect in the group without free 
fat mass loss during weight therapy; this contradicts 
the results of studies which have revealed that a lack 
of free fat mass loss during weight reduction therapy is 
a predictor of successful long-term weight maintenance 
[44, 45]. Surprisingly, the body fat gain was similar dur-
ing the five-year follow-up in both subgroups, although 
the percentage increase in relation to body fat mass 
after weight loss was higher in the subgroup with the 
yo-yo effect. An explanation for this finding is difficult. 
Perhaps women in the subgroup with the yo-yo ef-
fect maintained increased physical activity during the 
weight loss programme but returned to their previous 
eating habits, while subjects in the subgroup without 
the yo-yo effect maintained a sedentary lifestyle but 
changed their eating habits. This hypothesis is indirectly 
supported by the revealed changes of free fat mass in 
our study, as training prevents any loss of free fat mass 
during weight reduction therapy [46, 47]. Moreover, it 
has been shown that low-fat intake prevents weight 
regain [48, 49]. In the subgroup without the yo-yo ef-
fect, decreased free fat mass was found after 3-month 
weight loss therapy and further deteriorated during 
the five-year follow-up, while in the subgroup with the 
yo-yo effect free fat mass was constant during this time. 
Contrary to our findings, a recently published study 
revealed that weight loss therapy decreases fat mass 
and protects fat free mass regardless of the intervention 
applied (i.e. diet only, diet and aerobic training, diet and 
resistance training) in young overweight women [41].
The main limitation of our study is the size of the study 
group. Thus, larger longitudinal studies are necessary 
to clarify the effect of body mass cycling on systemic 
microinflammation. The lack of diet composition and 
physical activity assessment during both the weight 
loss period and the five-year follow-up is another weak 
point of our study. Moreover, the distribution of body 
fat and its visceral deposits were not directly assessed 
using DEXA or a CT scanner.
Conclusions
The yo-yo effect has a modest influence on systemic 
microinflammation and seems not to abolish the benefit 
achieved with a weight loss programme. This may sug-
gest that the persistence of changes in lifestyle imple-
mented during the programme such as regular physical 
activity and diet composition may have a significant 
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impact on the level of systemic microinflammation in 
the obese.
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